Final extension for AsiaPharm takeover set for May 22

MBK Partners stands firm on its takeover offer which, as of April 30, had been accepted by 77.19% of AsiaPharmÆs shareholders. Templeton remains opposed to the deal.

Private equity firm MBK PartnersÆ takeover offer for Singapore-listed drug company AsiaPharm Group has been extended to May 22, according to ABN Amro Bank, which is advising MBK on the deal.

MBK Partners has stood firm on the S$0.725 $0.53 per share offer price of Lu Ye Pharmaceutical Investment, which it controls, in a deal valued at S$357.4 million $262.6 million. The offer had been accepted by 77.19% of AsiaPharmÆs shareholders as of April 30. This includes...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: asiapharm | mbk

Print Edition

FinanceAsia Print Edition